Logo

Bruker Daltonik and VWR Sign Mass Spec Co-Marketing Pact

May 11, 2004

NEW YORK, May 11 (GenomeWeb News) - Bruker Daltonik, a subsidiary of Bruker BioSciences, today said that it has signed an agreement with VWR International's Scientific Instruments business unit to jointly market certain VWR HPLC and Bruker Daltonik bench-top mass spectrometers in Europe.

 

VWR International will market Bruker Daltonik's esquire4000 LC/MS/MS ion trap mass spectrometer in Europe along with with its LaChrom Elite HPLC system, while Bruker Daltonik will offer the LaChrom Elite with its own bench-top LC/MS Ion Trap and time-of-flight systems.

 

Bruker Daltonik's Compass LC/MS software suite will control both the LaChrom Elite HPLC system and the mass spectrometer detector, the companies said.

Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.